Form 4: Regeneron Pharmaceuticals Director George L. Sing Reports Stock Option Exercise and Share Disposals

Director George L. Sing exercised stock options and disposed of shares of Regeneron Pharmaceuticals on May 3, 2024.

Summary

• On May 3, 2024, George L. Sing, a director of Regeneron Pharmaceuticals, exercised non-qualified stock options to acquire 2,000 shares of common stock at a price of $413.33 per share.
• Following the exercise, Sing disposed of 877 shares of common stock at a price of $942.53 per share.
• After these transactions, Sing directly owns 27,472 shares of Regeneron common stock.
• Sing also indirectly owns 750 shares through a spouse, 400 shares through a spouse/custodial account for a son, and 1,000 shares through a trust for a son.
• Sing also directly owns 3,338 non-qualified stock options.

Sentiment

Score: 5

Explanation: Neutral sentiment as it's a standard disclosure of insider trading activity. The transactions themselves don't necessarily indicate a positive or negative outlook for the company.

Industry Context

This Form 4 filing is a routine disclosure of insider transactions, providing transparency to investors regarding the trading activities of company directors. It's a standard practice for publicly traded companies.

Stakeholder Impact

• The transactions provide transparency to shareholders regarding director's trading activities.
• The transactions may have a minor impact on the stock price due to the volume of shares involved.

Key Dates